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Microglia are resident immune cells of the CNS that
are activated by infection, neuronal injury, and
inflammation. Here, we utilize flow cytometry and
deep RNA sequencing of acutely isolated spinal
cord microglia to define their activation in vivo. Anal-
ysis of resting microglia identified 29 genes that
distinguish microglia from other CNS cells and pe-
ripheral macrophages/monocytes.We then analyzed
molecular changes in microglia during neurodegen-
erative disease activation using the SOD1G93Amouse
model of amyotrophic lateral sclerosis (ALS). We
found that SOD1G93A microglia are not derived from
infiltrating monocytes, and that both potentially neu-
roprotective and toxic factors, including Alzheimer’s
disease genes, are concurrently upregulated. Mutant
microglia differed from SOD1WT, lipopolysaccharide-
activated microglia, and M1/M2 macrophages,
defining an ALS-specific phenotype. Concurrent
messenger RNA/fluorescence-activated cell sorting
analysis revealed posttranscriptional regulation of
microglia surface receptors and T cell-associated
changes in the transcriptome. These results provide
insights into microglia biology and establish a
resource for future studies of neuroinflammation.INTRODUCTION
Microglia are motile cells that dynamically survey the CNS
parenchyma for invading pathogens and cell death (Nimmerjahn
et al., 2005). In addition, microglia actively participate in synaptic
pruning during development (Schafer et al., 2012). In response
to tissue injury, microglia undergo a rapid transition from resting,
ramified forms to amoeboid morphologies (Davalos et al., 2005).At present, little is known about the molecular changes that
occur in microglia during their activation, and whether these
changes are beneficial or harmful to neuron survival. Specific
transcriptional responses of microglia may vary depending on
the neuropathological condition and type of molecular stimuli
encountered (Ransohoff and Perry, 2009).
A common feature of neurodegenerative diseases is the pres-
ence of activated microglia in areas of neuronal death (Frank-
Cannon et al., 2009). Amyotrophic lateral sclerosis (ALS) is a
neurodegenerative disease characterized by progressive loss
of motor neurons, leading to paralysis and death. Microglia acti-
vation occurs robustly in ALS patient tissue and in spinal cords of
mutant SOD1 transgenic mice (Hall et al., 1998; McGeer and
McGeer, 2002). Analyses of chimeric mice have shown that
myeloid cells expressing mutant SOD1 are harmful to neurons
(Beers et al., 2006; Boille´e et al., 2006), consistent with a toxic
role of microglia or peripheral macrophages, which infiltrate
motor axons during disease progression (Chiu et al., 2009; Dibaj
et al., 2011; Graber et al., 2010). The depletion of proliferating
microglia does not affect survival in ALS mice (Gowing et al.,
2008). Additional studies have shown that T cells enter the ALS
spinal cord and slow disease progression by directing microglia
to express neurotrophic factors (Beers et al., 2008; Chiu et al.,
2008). Thus, the complex functional role of microglia ALS re-
mains to be determined.
Myeloid immune cells induce specific transcriptional programs
in response to various inflammatory stimuli (Gordon, 2003). In
macrophages, classical activation by the Thelper 1 (Th1) cytokine
interferon-g (IFN-g) or lipopolysaccharides (LPS) activates
an ‘‘M1’’ phenotype, whereas the Th2 cytokine interleukin-4
(IL-4) induces ‘‘M2’’ alternative macrophages (Gordon, 2003).
Although microglia are ontologically distinct from peripheral
macrophages, they have nevertheless been classified as M1-
or M2-like in ALS and Alzheimer’s disease (AD) (Beers et al.,
2011; Hickman et al., 2008; Michelucci et al., 2009). ALS micro-
glia have been reported to be proinflammatory and neurotoxic
in vitro (Sargsyan et al., 2011; Xiao et al., 2007). However, the
situation in the diseased spinal cord, where molecular changesCell Reports 4, 385–401, July 25, 2013 ª2013 The Authors 385
Figure 1. Transcriptional Profiling of Puri-
fied Spinal Cord Microglia and Parallel
Flow-Cytometry Analysis
(A) Percoll gradient isolated leukocytes from
SOD1G93A, non-Tg littermate, SOD1WT, and LPS-
injected mice were subjected to FACS analysis
(T cells and microglia) and CD11b+ microglia
purification for RNA-seq.
(B) Kaplan-Meier curves of disease progression in
SOD1G93A mice (n = 35), showing onset of hin-
dlimb weakness, peak weight, and death. Spinal
cords were dissected at day 65, day 100, and day
130/end stage for microglia analysis.
(C) Plots of the relative transcript levels of purified
microglia compared with whole spinal cord,
examining oligodendrocyte (Sox10, Mag, Mog,
Mobp, and Cldn11), astrocyte (Gfap, Slc1a2,
S100b, and Aldh1l1), motor neuron (Mnx1, Isl1,
Isl2, and Chat), and microglia (Cd11b, Cd45,
Cx3cr1, Iba1, and Cd68) markers. Values are fold
change ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001
by t test).
See also Figure S1.are likely influenced by amyriad of surrounding cell types, is likely
to be more complex. Thus, an analysis of acutely isolated micro-
glia from diseased mice may accurately reflect the complex
microenvironment of microglia in diseased spinal cord.
In this study, we performed molecular and immunological
profiling of microglia acutely isolated from ALS transgenic and
LPS-injected mice. A correlative analysis of spinal cord T cells,
surface protein expression, and transcriptome changes revealed
intricate phenotypic changes that occur in microglia during acti-
vation in vivo.386 Cell Reports 4, 385–401, July 25, 2013 ª2013 The AuthorsRESULTS
Deep RNA Sequencing of the Spinal
Cord Microglia Transcriptome
To analyze the transcriptomes of
acutely isolated microglia during activa-
tion, spinal cords were dissociated and
centrifuged over Percoll gradients to
isolate leukocytes (Sedgwick et al.,
1991). One fraction of the leukocytes
was analyzed by flow cytometry to
collect data on lymphocyte and micro-
glia surface phenotypes (Figure 1A),
and a separate fraction was used for
microglia purification by CD11b mag-
netic separation, as described previ-
ously (Cardona et al., 2006a). CD11b+
CD45lo microglia were obtained with
>96% purity from all samples at dif-
ferent disease time points (Figure S1).
Total RNA was extracted and deep
sequenced with paired ends, resulting
in transcriptome data that could be
directly correlated with FACS analysis
of the spinal cords (Figure 1A).We used SOD1G93A mice to study microglia activation. These
mice display progressive motor neuron degeneration and death
(Gurney et al., 1994; Figure 1B). Nontransgenic (non-Tg) and
wild-type SOD1 transgenic (SOD1WT) microglia were analyzed
as controls. We chose three time points based on disease pro-
gression in our SOD1G93A colony (n = 35; 17 females, 18 males;
Figure 1B). Motor weakness onset was defined by observation of
hindlimb tremors (mean ± SEM; 86.4 ± 1.05 days of age) and
measurement of peak weight (90.23 ± 2.44 days). Disease end
stage occurred at 131.6 ± 1.72 days of age. Microglia were
isolated at day 65 (presymptomatic), day 100 (early symptom-
atic), and day 130/end stage (Figure 1B, arrows; Figures S1A
and S1B). We also analyzed microglia activated by a single,
moderate dose of intraperitoneal LPS injection, and SOD1G93A
microglia from both B6/SJLF1 and B6 strain backgrounds
(Figure S1A).
We verified the purity of the microglia by comparing acutely
isolated microglia and whole spinal cord RNA sequencing
(RNA-seq) data. Oligodendrocyte (Sox10, Mag, Mog, Mobp,
and Cldn11), astrocyte (Gfap, Slc1a2, S100b, and Aldh1l1),
and motor neuron (Mnx1, Isl1, Isl2, and Chat) markers were not
detectable, whereas known microglia markers (Cd11b, Cd45,
Cx3Cr1, Aif1, and Cd68) were highly enriched following purifica-
tion (Figure 1C). A total of 42 microglia samples were sequenced
and 1.251 billion reads mapped to the genome, with an average
of 29.79 million reads/sample (Table S1). Normalized gene-
expression levels (reads per kilobase million [RPKM]) showed
minimal variation between biological replicates, whereas signifi-
cant differences were found between disparate sample groups
(i.e., mutant or WT microglia; Figure S1C).
Identification of Microglia-Specific Marker Genes
Currently, fewspecificmarkers thatdistinguishmicroglia frompe-
ripheral monocytes andmacrophages are known (Frank-Cannon
et al., 2009; Ransohoff and Perry, 2009). We used our whole-
transcriptome analysis to define specific markers for microglia.
First, we compared microglia RNA-seq data with RNA-seq data
obtained from astroglia, motor neurons, and whole spinal cord.
This comparison yielded 288 genes enriched in microglia by
5-foldcomparedwith theotherCNScell types (q<0.05; heatmap,
Figure 2A). We next compared microglia microarray data with
data from 22 other myeloid cell types collected by the Immu-
nological Genome Project (ImmGen), including subsets of
neutrophils, peripheral macrophages, and monocytes (Gautier
et al., 2012). This comparison yielded 99 genes enriched inmicro-
glia 5-fold relative to other myeloid immune cells (q < 0.05; heat-
map, Figure 2B). The overlap between these two distinct data set
comparisons (Venn diagram, Figure 2C) yielded 29 highly specific
markers for microglia relative to both CNS cell types and peri-
pheral myeloid immune cells (Table S2). The most enriched
microglia genes were Olfml3, Tmem119, and Siglec-H, which
were expressed at very high levels in microglia but barely
detected inmacrophagesandmonocytes (Figure 2D, toppanels).
By contrast, Iba1 (Aif1) and CD68, two widely used microglia
markers, showed expression in macrophages, neutrophils, and
monocytes (Figure 2D, bottom panels). Cx3cr1 is extensively
used to characterize microglia dynamics in vivo (Cardona et al.,
2006b; Nimmerjahn et al., 2005; Schafer et al., 2012).
However, Cx3cr1 ranks 24th on our list of 29 microglia-enriched
genes in comparison with other myeloid cells, and is not
as specific as Olfml3, Tmem119, or Siglec-H (Figure 2D; Table
S2). We note that Cx3cr1 remains a good marker for microglia,
as it is not expressed on neuroepithelial cells (Cardona
et al., 2006a) and is not characteristic of CNS-infiltrating
mononuclear myeloid cells (Mizutani et al., 2012).
We confirmed microglia-specific expression of Siglec-H and
Olfml3 by flow cytometry and immunostaining (Figures 2E, 3C,
and S2). As indicated by FACS, the spleen, liver, and lymphnode macrophages did not express Siglec-H, but it was ex-
pressed on spinal cord and brain microglia (Figure 2E). We
note that although these markers distinguish microglia from
peripheral macrophages, they may be expressed by other
immune cells. For example, Siglec-H is a knownmarker for plas-
macytoid dendritic cells (DCs), a lymphoid cell type and source
of type 1 IFNs (Loschko et al., 2011). We confirmed that splenic
and lymph node plasmacytoid DCs (CD11b+CD11c+B220+) ex-
pressed Siglec-H, but myeloid DCs (CD11b+CD11c+B220)
and macrophages (CD11b+CD11c) did not (Figure S2).
Resident Microglia Increase in Spinal Cords during
Disease Progression, but Monocytes Do Not
We carried out FACS analyses to characterize myeloid cell
populations in the spinal cords of SOD1G93A mice, and observed
an increase in the CD11b+ population with disease progression
(Figure 3A). In addition, RNA-seq analysis showed that the
microglia-specific messenger RNA (mRNA) transcripts Olfml3,
Tmem119, and Siglec-H increased over time in whole SOD1G93A
spinal cord (Figure 3B). Immunostaining confirmed that Olfml3
protein was expressed in resting microglia and increased in
SOD1G93A spinal cords (Figure 3C). In the same sections, mono-
cytes known to infiltrate SOD1G93A peripheral ventral roots (Chiu
et al., 2009; Graber et al., 2010) were negative for Olfml3, con-
firming the marker’s specificity for microglia (Figure 3C). These
data indicate that microglia activation may affect the overall spi-
nal cord transcriptional signature. By overlaying the 29 microglia
markers onto volcano data plots of spinal cord RNA-seq data
(p value versus fold change), we detected a significant increase
of the microglia signature in SOD1G93A spinal cord with disease
progression (Figure 3D). However, purified SOD1G93A microglia
actually showed a decrease in the levels of these microglia tran-
script markers (Figure S3). These observations suggest that the
increase in microglia-specific transcripts observed in whole
spinal cords is due to expansion of the number of microglia
and not to an increase in the expression of microglia-specific
markers on a per-cell basis in the spinal cord.
Based on immune-cell analysis in SOD1G93A mice, Butovsky
et al. (2012) recently reported that a significant population of
Ly6Chi monocytes are recruited to the spinal cord and become
activated microglia during disease progression. However, this
conclusion is at odds with the report that microglia in the
SOD1G93A mouse spinal cord are resident derived cells, based
on analysis of circulation-conjoined GFP parabiosis studies
(Ajami et al., 2007). In addition, our FACS analysis of SOD1G93A
spinal cord shows that very few microglia (<0.5%; CD11b+
CD45+) are Ly6C+ (Figures 3E and 3F), which is inconsistent
with the findings of Butovsky et al. (2012). The few Ly6C+ cells
we observed also expressed TCRb, showing that they were
T cells and notmonocytes (Figure S3B).We also analyzedmono-
cyte marker expression in transcriptional profiling data and by
quantitative PCR (qPCR). The levels of Ly6c1 and Ccr2, two
markers of peripheral monocytes (Mildner et al., 2007), did not
increase in SOD1G93A spinal cord (Figure S3D) or in purified
microglia (Figure 3G). Thus, taken together, our data corroborate
experiments by Ajami et al. (2007) indicating that resident micro-
glia, but not peripheral monocytes, are major participants in ALS
spinal cord innate immune activation.Cell Reports 4, 385–401, July 25, 2013 ª2013 The Authors 387
(legend on next page)
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Microglia Coexpress Potentially Neuroprotective and
Toxic Factors in ALS Mice
We next analyzed microglia transcriptional changes during
neurodegeneration in ALS transgenic mice. Unsupervised hier-
archical clustering segregated mutant SOD1G93A microglia
groups into distinct clusters that were age-dependent and
separate from control microglia (Figure 4A). SOD1WT microglia
and non-Tg microglia showed similar gene expression at day
130 (71 differentially expressed [DE], 2-fold, p < 0.01; Fig-
ure S4), indicating that overexpression of the human SOD1
enzyme in mice does not significantly alter microglia gene
expression. By contrast, SOD1G93A microglia differed signifi-
cantly from non-Tg microglia at end stage/day 130 (1,041 DE
genes, 2-fold, p < 0.01; Figure S4A). ALS and control micro-
glia differed most significantly at postsymptomatic time points
(day 65: 956 DE genes; day 100: 1,619 DE genes; end stage:
1,866 DE genes; 2-fold, p < 0.05; Figure S4C). Venn diagrams
reveal hundreds of significant transcript changes between
SOD1G93A and control microglia at each disease time point,
with 122 shared transcripts that were up- or downregulated
at all three time points (Figure 4B; DE gene lists in Table S3),
mostly in a progressive, age-dependent manner (Figure S4D).
Principal-component analysis (PCA) revealed that one principal
component (PC1) separated SOD1G93A and control microglia
profiles over time (Figure S4E). These findings are consistent
with prior analyses showing that symptom onset marks a tran-
sition point for microglia activation (Chiu et al., 2009), and that
genetic manipulation of microglia affects the postsymptomatic
phase in mutant SOD1 mice (Beers et al., 2006; Boille´e et al.,
2006).
Analysis of the most DE genes (Figure 4C) revealed that
SOD1G93A microglia show significant induction of potentially
neuroprotective and neurotoxic factors concurrently during
ALS disease progression. Insulin-like growth factor 1 (Igf1),
which activates AKT prosurvival signaling in motor neurons,
has been shown to extend lifespan when delivered into ALS
mice (Kaspar et al., 2003; Narai et al., 2005). Igf1 was upregu-
lated over time in mutant microglia, showing a 34-fold increase
compared with control microglia at end stage (Figures 4D and
4E). Progranulin (Grn) was also strongly upregulated by mutant
microglia (3.9-fold at end stage; Figure 4D). Progranulin is a pro-
survival factor released by microglia that acts on neurons. Grn
mutations are linked to frontotemporal dementia (Rosen et al.,
2011), and genetic ablation experiments have shown that pro-
granulin is neuroprotective in ALS zebrafish models (Laird
et al., 2010; Ryan et al., 2009). We found other potentially
beneficial factors that were upregulated by SOD1G93A microgliaFigure 2. Microglia Marker Identification by Transcriptome Compariso
(A) Heatmap of the top 50 genes enriched in microglia compared with CNS cell t
(B) Heatmap of the top 50 genes enriched in microglia compared with neutroph
(q < 0.05, >5-fold enrichment).
(C) Venn diagrams show that 29 genes distinguish microglia from other CNS and
(D) Plots of transcript levels across neutrophil, macrophage, monocyte subtyp
Tmem119 are highly enriched markers for microglia. By contrast, Iba1 (Aif1), Cd
(E) FACS of Siglec H expression on CD11b+CD45+ myeloid cells isolated from the
expression was restricted to CNS microglia (red, stained cells; gray, unstained c
See also Figure S2.during disease progression, including Trem2 (Trem2) and its
downstream adaptor molecule Dap12 (Tyrobp; Figures 4D and
S5). Trem2 is a single-pass transmembrane protein that
triggers myeloid cells and is thought to increase phagocytic
activity and suppress cytokine production (Melchior et al.,
2010; Thrash et al., 2009). Trem2/Dap12 mutations lead to
Nasu-Hakola disease, a cognitive disorder caused by microglia
dysfunction that arises from homozygous or compound-hetero-
zygous Trem2 gene deletion, and also includes osteoclast
dysfunction (Guerreiro et al., 2013b; Thrash et al., 2009).
Trem2 variants were recently shown to increase the risk of AD,
and its expression is upregulated in an AD mouse model (Guer-
reiro et al., 2013a).
At the same time, SOD1G93A microglia expressed potentially
neurotoxic factors. Matrix metalloproteinase 12 (Mmp12) was
among the most significantly induced molecules, with an in-
crease of 125-fold compared with control microglia at end stage
(Figures 4D and 4E). Inhibition of MMPs has been shown to
extend lifespan in ALS mice (Lorenzl et al., 2006), but the partic-
ular role of MMP-12 has not yet been defined. Optineurin (Optn)
is also significantly upregulated in mutant microglia (Figure 4D).
Mutations in Optn are a cause of familial ALS (Maruyama et al.,
2010), and expression of mutant optineurin leads to deregulation
of IFN signaling, suggesting a deleterious role in disease pro-
gression (Sakaguchi et al., 2011). We also analyzed changes in
cytokine-related gene expression (Figure S5C). Tumor necrosis
factor a (TNF-a), IL-1b, and IL-a levels increased in SOD1G93A
microglia, along with receptors for type 1 IFNs (Ifnar1 and Ifnar2)
and IL-10 (IL-10ra). Several IFN response genes (Ifit1, Ifit3,
Ifitm3, and Igip30) increased significantly during disease pro-
gression in SOD1G93A microglia (Figure S5C). The proinflamma-
tory oxidase Nox2 (Cybb) was also upregulated in SOD1G93A
microglia, and pharmacological and knockout studies have
shown that Nox2 is harmful to ALS mice (Harraz et al., 2008; Fig-
ure 4D). We also found significant upregulation of the secreted
factor osteopontin (Spp1; Figure S5A). Osteopontin may be neu-
rotoxic or neuroprotective, as it has been shown to contribute
to disease progression in autoimmune encephalomyelitis (Cha-
bas et al., 2001) and is upregulated in AD cerebral spinal fluid,
but is neuroprotective in animal models of spinal cord injury
(Comi et al., 2010; Hashimoto et al., 2007). The robust upregula-
tion of IGF-1, MMP-12, and osteopontin in activated SOD1G93A
microglia was confirmed by immunostaining of Iba1+ microglia
in spinal cord sections (Figures 4E and S5B). Thus, ALS trans-
genic microglia display a complex transcriptional profile, ex-
pressing both potentially neuroprotective and neurotoxic factors
concurrently.ns with Other CNS and Myeloid Immune Cell Types
ypes by RNA-seq, ranked by fold change (q < 0.05, >5-fold enrichment).
il, macrophage, and monocyte subsets by microarray, ranked by fold change
peripheral myeloid cells.
es, and microglia (n = 3–5 arrays/group; mean ± SEM). Olfml3, Siglech, and
68, and Cx3cr1 are expressed by other myeloid cell types.
spleen, lymph node, liver, spinal cord, and brain of the same animals. Siglec H
ells).
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Figure 3. SOD1G93A Spinal Cord Immune Activation Is Characterized by Resident Microglia and Not Peripheral Monocytes
(A) FACS analysis and cell quantification show increases in CD11b+ myeloid cells in SOD1G93A spinal cords over time (**p < 0.01). Error bars: mean ± SEM.
(B) Transcript-level comparisons of whole spinal cord RNA show increases in the microglia markersOlfml3, Tmem119, and Siglech in SOD1G93A versus SOD1WT
mice. Error bars: mean ± SEM.
(C) Immunostaining shows Olfml3 expression in resting microglia (CD11b+) in non-Tg spinal cord. At end stage, activated SOD1G93A microglia in ventral horns
express Olfml3, but nerve-root-activated macrophages do not. Scale bars: 100 mm.
(legend continued on next page)
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SOD1G93A Microglia Differ Significantly from
LPS-Induced Microglia and M1 or M2 Macrophages
In the periphery, macrophages adopt an M1 phenotype when
activated by LPS to combat bacterial pathogens; by contrast,
IL-4-activated macrophages adopt an M2 phenotype to
combat parasitic infections (Gordon, 2003). In inflammatory
conditions, M2 macrophages are involved in wound healing
and regulation of insulin resistance (Odegaard et al., 2007).
Despite ontological differences between microglia and periph-
eral macrophages, microglia have also been categorized as
M1- or M2-like (Appel et al., 2011; Beers et al., 2011). During dis-
ease progression in SOD1G93A mice, microglia have been re-
ported to adopt an M2 protective phenotype that transitions
to an M1 neurotoxic phenotype over time (Beers et al., 2011;
Vaknin et al., 2011). However, these analyses involved whole
spinal cord expression of a small subset of M1 or M2 macro-
phage genes (Beers et al., 2011). We addressed the similarities
in the ALS microglia profile with M1/M2 activation using two
approaches.
First, we compared microglia transcriptomes from SOD1G93A
mice with those of microglia activated by LPS injection. We
found that these two modes of microglia activation differed
significantly (Figure 5A): SOD1G93Amicroglia induced expression
of cathepsin D, C1qa, ApoE, and Trem2, whereas LPS-activated
microglia showed high expression of Bag5, Stat3, and Adamts1.
SOD1G93A microglia transcriptomes (B6 and B6SJL strains)
segregated distinctly from LPS-activated microglia (Figure S6).
Relative to naive microglia, SOD1G93A activation induced 1,158
genes and LPS activation induced 499 genes, with 730 shared
activation genes (2-fold, p < 0.05; Figure S6B). Pathway analysis
by Database for Annotation, Visualization and Integrated
Discovery (DAVID) showed that SOD1G93Amicroglia upregulated
genes in Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways for Mus musculus involving ribosome function
(mmu03010), lysosome (mmu04142), and oxidative phosphory-
lation (mmu00190; Figure 5B). Strikingly, ALS microglia were
also enriched in the transcripts of genes related to neurodegen-
erative diseases, including Huntington’s disease (mmu05016),
Parkinson’s disease (mmu05012), and AD (mmu05010). Con-
versely, LPS-activated microglia were enriched in DNA replica-
tion (mmu03030), cell cycle (mmu04110), and innate immune
signaling through the RIG-I-like receptor (mmu04622) and
Nod-like receptor (mmu04621; Figure 5B). We conclude that
ALS and LPS microglia display distinct modes of activation.
We next mined published microarray data sets of M1 and
M2 macrophage activation for genome-wide transcriptional
changes that occur for each mode of activation (Shell et al.,
2005; Szanto et al., 2010). This analysis yielded 157M1-enriched
and 307 M2-enriched macrophage activation genes (p < 0.01,(D) Microglia signature genes (red) show progressive increases on volcano plots
p value). Percentages denote the proportion of microglia genes expressed >1.5-
(E) CD45+ spinal cord leukocytes were analyzed for lymphocyte, monocyte, and
greater proportions of CD11bCD45hi lymphocytes comparedwith non-Tg contro
microglia (99.9%, G93A versus 99.5%, non-Tg), and not Ly6C+ monocytes (0.37
(F) Quantification of FACS analysis (n = 14–16 per group). Error bars: mean ± SE
(G) By qPCR, the monocyte markers Ccr2 and Ly6c1 are not upregulated in puri
See also Figure S3.2-fold induced and nonoverlapping; Figure 5C). These M1 and
M2 gene lists were analyzed within purified SOD1G93A versus
control microglia data sets (Figure 5D). At day 65, the proportions
of M1 or M2 genes that were upregulated in SOD1G93A com-
pared with control microglia were similar (M1 genes: 97/157 =
61.8%; M2 genes: 187/307 = 61.1%). The proportion of M1 acti-
vation genes, but not M2 genes, slightly increased in SOD1G93A
microglia at day 100 (M1: 106/157 = 67.5%; M2: 190/307 =
62.1%) and at end stage (M1: 111/157 = 70.7%; M2: 184/
307 = 59.80%). This analysis clearly shows that SOD1G93A
microglia do not display a significant bias toward either M1 or
M2 phenotypes at any time point during disease progression.
This conclusion was confirmed by fold-change analysis across
macrophage and microglia data sets of known M2 markers
(Ym1 and Arginase 2) or M1 markers (TNF-a and IL-1b; Fig-
ure 5E). Moreover, Igf1 and Axl, two highly induced transcripts
in SOD1G93A microglia (Figure 5E), were not enriched in either
M1- or M2-activated macrophages. These data unequivocally
demonstrate that the microglia phenotype in ALS mice is
neurodegeneration-specific and is unrelated toM1 orM2macro-
phage-like states.
Lysosomal and AD Pathways Are Induced in Mutant
SOD1 Microglia
We next analyzed changes in the microglia transcriptome during
ALS disease progression using an information-theoretic path-
way analysis called iPAGE (https://tavazoielab.c2b2.columbia.
edu/iPAGE/; Goodarzi et al., 2009). Using a supervised clus-
tering approach, we grouped genes into 15 clusters (C0–C14),
where cluster C0 represents a background cluster to which the
transcripts without significant differential expression were
assigned. The other clusters show distinct expression patterns
and are informative of pathways involved in microglia activation.
iPAGE identified clusters C3 and C4 as being particularly en-
riched in SOD1G93A microglia (Figure S7). A number of KEGG
pathways were significantly enriched in SOD1G93A clusters, in
particular the lysosome (mmu4142), AD (mmu5010), and spli-
ceosome (mmu3040) pathways (Figure 6A). A similar analysis
based on Gene Ontology (GO) terms found related biological
processes associated with SOD1G93A microglia: lytic vacuole
(GO:0000323), RNA splicing (GO:0008380), and organelle inner
membrane (GO:0019866; Figure S7B). Differential expression
gene clusters C2, C8, and C14 correspond to control micro-
glia-enriched genes. We found that control microglia were signif-
icantly enriched in insulin signaling (KEGG: mmu4910), growth
factor binding (GO:0019838), and aromatic compound meta-
bolism (GO:0006725) pathways. As an alternative method to
analyze the feature-rich data set, we also used a time-point
normalization approach for analysis, in which transcripts wereof SOD1G93A versus SOD1WT spinal cord RNA-seq data (fold change versus
fold (dotted line) in SOD1G93A spinal cord.
microglia populations by FACS. At end stage, SOD1G93A spinal cords showed
ls (2.38% versus 0.221%). Within CD11b+myeloid cells, themajority are Ly6C
%, G93A versus 0.0977%, non-Tg).
M.
fied SOD1G93A microglia at end stage. Relative expression ± SEM (**p < 0.01).
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clustered based on their relative expression levels across time
points (Figure S7C).
Using FIRE regulatory element analysis (Elemento et al., 2007),
we found significant enrichment for three transcriptional motifs
associated with differential regulation of pathways in activated
SOD1G93A microglia (Figure 6B). CCCCGCC, an optimized bind-
ing motif for KLF9 (a repressor) and Sp1, which compete for
binding sites, was enriched in genes involved in lysosome and
cell-cycle pathway dysregulation (Figure 6B). The transcript
levels of KLF9 were inversely correlated with motif-enriched
clusters (0.49, p = 0.002), which might be KLF9 target genes
(Figure S8). AcCGGaAc, a motif for ELK-4, was enriched for spli-
ceosome and ribosome pathway genes, and the transcript levels
of ELK-4 correlated directly with motif expression in mutant
microglia (Figures 6B and S8A). These results suggest that
KLF9 downregulation and ELK-4 upregulation are potentially
linked to induction of lysosome, ribosome, and spliceosome
changes in mutant microglia.
The induction of lysosome and AD pathways in SOD1G93A
microglia may hold functional implications related to protein
clearance and neurodegeneration. K-means analysis clustered
coregulated genes in the lysosome pathway (Figure S8B),
including a host of lysosome enzymes (e.g., HexA), membrane
markers (e.g.,Cd68,Cd63, and Lamp1), components of the lyso-
somal ATPase (e.g., Atp6v0d1), and a large group of cathepsins
(Ctsa, Ctsb, Ctsd, Ctsl, Ctss, Ctsz, and Ctse). Cathepsin expres-
sion wasmostly coregulated in gene cluster 1 (except forCtse). It
remains to be determined whether KLF9, as predicted above,
plays a role in expressing specific clusters of lysosome genes.
Cathepsins are activated by the low pH of lysosomes, whose
deficiencies have been linked to increased neurodegeneration.
Cathepsin B mediates b-amyloid plaque removal in AD (Sun
et al., 2008), and cathepsin S degrades antigenic proteins for
presentation on major histocompatibility complex (MHC) class
II (Wendt et al., 2008). Cathepsin D deficiency results in CNS
lysosomal storage disease with ceroid lipofuscin accumulation
(Santambrogio et al., 2001). We confirmed that cathepsins B
and S are expressed in SOD1G93A microglia by spinal cord
immunostaining (Figure S8C).
AD genes were found to be enriched in SOD1G93A microglia,
both by targeted pathway analysis (Figure 5B) and by global tran-
scriptome analysis using iPAGE (Figure 6A). K-means clustering
showed six groups of regulated AD genes in mutant and control
microglia (Figure 6C) that included components of ATP syn-
thase, cytochrome C oxidase, and NADH dehydrogenase,
enzymes that are present in the mitochondrial envelope and
involved in energy metabolism. Misfolded SOD1 aggregatesFigure 4. SOD1G93A Microglia Progressively Upregulate Potentially Ne
(A) Hierarchical clustering of RNA-seq data from SOD1G93A, SOD1WT, and non-T
control transcriptomes.
(B) Differentially upregulated or downregulated genes (2-fold difference, p < 0.
displayed as Venn diagrams.
(C) Heatmap displaying the 40 most DE genes across all data sets (ranked by co
(D) Microglia significantly upregulate potentially neuroprotective (IGF-1, progranu
disease progression (*p < 0.05; **p < 0.01; ***p < 0.001 by t test). Error bars: me
(E) Immunostaining for IGF-1, MMP-12, and microglia (Iba1) in SOD1G93A (end sta
high-magnification images of microglia. Scale bars: 100 mm.
See also Figures S4 and S5.also localize to the mitochondrial inner membrane (Liu et al.,
2004; Pasinelli et al., 2004). Interestingly, SOD1G93A microglia
showed significant upregulation of three genes whosemutations
are directly linked to AD susceptibility: Tau (Mapt), Presenilin 2
(Psen2 [Psen2]), and Apolipoprotein E (ApoE [Apoe]; Figure 6C).
Mapt (tau) was induced at day 65 and downregulated over time,
whereas Psen2 and Apoe were progressively upregulated in
SOD1G93A microglia. Apoe was one of the most significantly ex-
pressed and induced transcripts during disease progression
(>1,000 RPKM, 64-fold at end stage; Figure 6E). This upregula-
tion was specific to SOD1G93A microglia, as Apoe was not
induced by LPS activation or inM1/M2macrophages (Figure 5A).
Immunostaining revealed robust ApoE expression throughout
the ventral horns of SOD1G93A but not non-Tg spinal cord; this
staining was enriched in Iba1+ microglia cytoplasms (Figure 6F).
Thus, AD pathway genes are amajor component of themicroglia
activation profile in SOD1G93A mice.
Microglia Transcriptome Changes Relate to Surface
Marker Acquisition and T Cell Infiltration
We performed an analysis of spinal cord FACS data in relation
to microglia RNA-seq data from the same mice (Table S4).
SOD1G93A microglia were found to upregulate cell-surface
expression of CD11c (DC marker), CD86 (costimulatory ligand),
and CD11b (integrin aM) (Figure 7A). The surface mean fluores-
cence intensity (MFI) and transcript levels for these genes
increased concurrently (Figure 7B). However, the analysis
showed different relationships between surface expression
and transcriptional expression (Figure 7C). Increased Cd11c
(Itgax) mRNA levels correlated with CD11c surface levels by
FACS (r2 = 0.83). However, CD11b surface levels did not corre-
late with CD11b (Itgam) transcript levels (r2 = 0.006). Similarly,
CD86 surface levels increased over time to a greater extent
than Cd86 mRNA levels (r2 = 0.16). Thus, microglia CD11c sur-
face expression is controlled directly by transcriptional changes,
whereas CD11b and CD86 surface induction occurs through
posttranscriptional mechanisms. In dendritic cells, CD86 surface
expression is regulated by MARCH1 ubiquitination (Corcoran
et al., 2011), and it remains to be determined whether microglia
utilize similar pathways. Thus, microglia functional activation in-
volves transcriptional and posttranscriptional regulation. Whole-
proteome analyses are required to establish a complete picture
of ALS microglia activation.
FACS analyses revealed that the percentage of CD4+ Thelper
cells and CD8+ Tcytotoxic cells infiltrating mutant spinal cords
increased significantly over time compared with controls (Fig-
ures 7D and 7E). Spearman rank was used to correlate CD4+uroprotective and Neurotoxic Factors
g microglia at different time points shows distinct segregation of mutant from
05) in mutant microglia compared with control microglia at each time point,
efficient of variance), shown by genotype and time point.
lin, and DAP12) and neurotoxic factors (MMP-12, optineurin, and Nox2) during
an ± SEM.
ge) and non-Tg spinal cords (day 130). Top panels: ventral horn; lower panels:
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Figure 5. ALS Spinal Cord Microglia Do Not Resemble LPS-Activated Microglia or M1 and M2 Macrophages
(A) Profiles of SOD1G93A end-stage microglia are compared with those of microglia activated by LPS injection. Lines show 2-fold change boundaries; specific
enriched genes are highlighted.
(B) SOD1G93A- or LPS-activation-inducedgenes (1.5-fold, p<0.05comparedwith naivemice) showdifferential KEGGpathwayenrichment (heatmap, -logp value).
(legend continued on next page)
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and CD8+ T cell populations to corresponding gene-expression
levels in microglia at all time points (Figures 7D and 7E). Both
subsets were related to microglia expression of pathways that
are relevant to antigen presentation: vacuole organization
(GO:0007033) genes and protein ubiquitination (GO:0016567).
Each subset was uniquely linked to different microglia GO cate-
gories: CD4+ T cells correlatedwithmicroglia expression of reac-
tive oxygen species (GO:0000302), oxidative phosphorylation
(GO:0006119), and humoral immune response (GO:0006959)
genes, whereas CD8+ T cells were associated with enrichment
in microglia phagocytosis (GO:0006909) and coenzyme meta-
bolism (GO:0006752) genes. These data may reflect active
T cell-microglia interactions during neurodegeneration.
DISCUSSION
Since their discovery by del Rio Hortega, microglia have been
linked to diseases of the CNS (Ransohoff and Perry, 2009).
Microglia respond rapidly to injury, transitioning from finely
branched, ramified forms to amoeboid morphologies (Frank-
Cannon et al., 2009). In this study, we detail transcriptional
changes that occur in microglia during activation in ALS
transgenic mice and following injection by LPS. We find that
SOD1G93A microglia adopt a dual phenotype, expressing fac-
tors that are hypothesized to be both neurotoxic and neu-
roprotective. The balance between toxicity and neuroprotection
is likely affected by cell-intrinsic factors and the spinal cord
microenvironment. Nonspecific anti-inflammatory drugs, such
asminocycline, would negate both of these aspects of microglia,
and may explain past failures in clinical trials (Gordon et al.,
2007).
Unlike other nervous system cells that derive from the ecto-
derm, recent work has shown that microglia originate from eryth-
romyeloid progenitors during embryonic hematopoiesis (Alliot
et al., 1991; Ginhoux et al., 2010; Kierdorf et al., 2013; Schulz
et al., 2012). Due to the paucity of specificmicroglia markers, tar-
geted analysis of neuroinflammation has been difficult. CD11b-
Cre and LysM-Cre transgenic mice have been used to study
microglia (Boille´e et al., 2006; Cho et al., 2008), but these genes
are also expressed by peripheral myeloid immune cells. A
mixture of monocytes and microglia participate in stroke, multi-
ple sclerosis, and spinal cord injury (Frank-Cannon et al., 2009;
Ransohoff and Perry, 2009). Thus, the identification of microglia
markers would provide useful tools for both genetic and immu-
nohistochemical analyses of these cells. To this end, we used
RNA-seq and microarray data to find 29 enriched markers ex-
pressed by microglia but not by CNS or peripheral myeloid cells.
Previous transcriptome analysis comparing related peripheral
immune cell types (B cells and T cells) identified few cell-specific
genes (Heng et al., 2008; Painter et al., 2011). By contrast, our
analysis suggests that microglia differ substantially from periph-(C) Volcano plots identify M1- or M2-activation-induced genes (2-fold, p < 0.01).
(D) M1 or M2 macrophage genes were overlaid onto volcano plots of SOD1G93A v
genes that were downregulated (left) or upregulated (right) in SOD1G93A microgli
(E) Fold-change induction for prototypic M2 macrophage genes (Arginase 1 and
SOD1G93A microglia activation. Error bars: mean ± SEM.
See also Figure S6.eral myeloid cells, which may reflect their early divergence in
ontology (Cuadros and Navascue´s, 1998).
Given the transcriptional differences between microglia and
peripheral macrophages, it is likely that they would also show
differences in transcriptional activation. Nonetheless, microglia
have often been designated as M1 or M2 macrophage-like
(Beers et al., 2008, 2011; Hickman et al., 2008; Ransohoff and
Perry, 2009). Our analysis using transcriptome data from M1
and M2 macrophage activation revealed that ALS microglia are
not similar to either activation modality, but rather express a neu-
rodegeneration-specific signature.
Butovsky et al. (2012) recently proposed that peripheral mono-
cytes infiltrate the ALS spinal cord and contribute substantially to
motor neuron loss. However, this observation is inconsistent
with previous parabiosis experiments (Ajami et al., 2007). Our
flow cytometry, transcriptional analyses, and qPCR data did
not reveal an induction of monocyte markers in SOD1G93A spinal
cords or purified CD11b+ microglia at any disease stage. More-
over, bone marrow transplantation, which Butovsky et al. (2012)
used as a second line of evidence, is known to introduce irradi-
ation-induced breakdown of the blood-brain barrier and mono-
cyte entry into the CNS (Ajami et al., 2007; Mildner et al.,
2007). We are in communication with Butovsky et al. to under-
stand these discrepant results. We note that our data do not
rule out a role for circulating monocytes in SOD1G93A mice, but
indicate only that they do not contribute to spinal cord inflamma-
tion. We and others (Chiu et al., 2009; Graber et al., 2010; Lince-
cumet al., 2010) have found substantial monocyte infiltration into
degenerating peripheral nerves in SOD1G93A mice, which may
play a role in affecting motor axon survival.
Our detailed transcriptome analysis reveals that resident ALS
microglia play a complex role. We found that microglia induce
factors that can suppress neurodegeneration, including IGF-1
(Igf1) and progranulin (Grn), which have been shown to mediate
motor neuron protection in ALS animal models (Kaspar et al.,
2003; Laird et al., 2010; Ryan et al., 2009). Pathway analyses
revealed significant upregulation of lysosomal proteins and
enzymes, including cathepsins (Figure S8). Cathepsins proteo-
lytically degrade and clear phagocytosed debris, including mis-
folded Ab aggregates in AD and a-synuclein in Parkinson’s
disease (Cullen et al., 2009; Sun et al., 2008). We hypothesize
that cathepsins may be involved in removing mutant SOD1
aggregates and neuronal debris in ALS mice, and that IGF-1
and progranulin are concurrently released as neuroprotective
factors in a wound-healing-type response.
ALS microglia also upregulate factors that have been linked to
neurotoxicity, including Nox2. At the protein level, mutant SOD1
aberrantly associates with Rac1 GTPase, which in turn deregu-
lates NADPH oxidase (Nox2) activity and increases reactive
oxygen species (Harraz et al., 2008). It may be that signaling
downstream of mutant SOD1 also turns on neurotoxic geneVenn diagram shows hallmark genes for each activation modality.
ersus control microglia (p value versus fold change). The numbers of M1 or M2
a at each time point are displayed.
YM1), M1 genes (TNF-a and IL-1b), and IGF-1 or Axl during macrophage or
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Figure 6. Pathway Analysis Shows Dysregulation of AD Genes in Mutant SOD1 Microglia
(A) iPAGE analysis finds significant enrichment for ribosomal, lysosome, RNA splicing, and AD KEGG pathways in SOD1G93A microglia compared with control
microglia (clusters C3 and C4).
(B) Transcriptional motif enrichment analysis finds three positively enriched transcriptional motifs linked to KEGG pathway changes.
(legend continued on next page)
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expression. Although removal of mutant SOD1 from myeloid
cells by conditional deletion ameliorates disease (Boille´e et al.,
2006), elimination of proliferating microglia (60% of the popula-
tion) in ALS mice does not affect survival (Gowing et al., 2008).
These results may reflect the multifaceted role of microglia in
ALS (Henkel et al., 2009).
An unexpected finding was a robust increase in microglia
expression of AD pathway genes during disease progression.
Mapt (tau), Psen2, and Apoe, genes, whose mutations are
directly linked to familial AD, were upregulated. The amyloid pre-
cursor protein (APP) processing products secreted APP (sAPP)
and Ab accumulate in ALS patient spinal cords and cerebrospi-
nal fluid (Calingasan et al., 2005; Steinacker et al., 2009). Apoε4,
the allele linked to early-onset AD, is associated with increased
risk for the bulbar-onset form of ALS (Praline et al., 2011).
Furthermore, Trem2, a microglia receptor that is upregulated
during disease progression, was recently linked to AD suscepti-
bility (Guerreiro et al., 2013a). What is the potential role of this AD
gene induction? Cramer et al. (2012) recently showed that reti-
noid X receptor stimulation leads to increased Apoe expression
in astrocytes and microglia, which leads to a major beneficial
impact on plaque clearance and cognitive performance in APP
transgenic mice. Furthermore, this is likely mediated through
the suppression of proinflammatory pathways and induction of
anti-inflammatory pathways in microglia (Mandrekar-Colucci
et al., 2012). It is possible that the microglia transcriptional re-
sponses we observe, including Apoe, Igf1, and Grn induction,
are programmed responses to neuronal death or injury.
Overall, we conclude that ALS microglia may be a double-
edged sword, with SOD1G93A-induced negative changes being
counterbalanced by a neuroprotective response mediated by
extrinsic regulatory factors, including signals released by dying
motor neurons and infiltrating T cells. Cx3cl1 expression on
motor neurons was shown to downregulate microglia activity in
ALS mice through the fractalkine receptor (Cx3cr1) (Cardona
et al., 2006b). T cells also play a key role in regulating microglia
function in ALS mice (Beers et al., 2008; Chiu et al., 2009). Using
FACS-transcriptome comparisons, we identified potential mo-
lecular pathways involved in T cell-microglia crosstalk in ALS
mice. Based on these analyses, microglia gene expression
pathways, which correlate with both CD4+ and CD8+ T cells,
may be involved in initiating their activation. CD8+ T cells may
then stimulate phagocytosis and CD4+ T cells may induce
oxidative phosphorylation in microglia (Figure 7).
This study demonstrates the utility of transcriptome-wide ana-
lyses of acutely isolated microglia in neurodegenerative disease
models. Our methodology and database capture the complex
nature of glial activation in vivo, showing a distinct advantage(C) SOD1G93A microglia show significant dysregulation in AD genes, as shown in
(D) AD pathway genes were grouped by K-means clustering and plotted over time
mutations link directly to AD and components of ATP synthase, NADH dehydrog
increased in SOD1G93A microglia.
(E) Psen2 (Psen2) and ApoE (Apoe) levels are upregulated in SOD1G93Amicroglia b
bars: mean ± SEM.
(F) Immunostaining of spinal cord sections shows significant upregulation of ApoE
Higher-magnification images show microglia (Iba1+) colocalization with ApoE. Sc
See also Figure S7.over culture-based studies of microglia activation, which nor-
mally involve neonatal-brain-derived cells. Elegant transcrip-
tional profiling studies have revealed significant differences
between astrocytes acutely isolated from the CNS and cultured
astrocytes, which appear to reflect an artifactual activation
phenotype (Foo et al., 2011).Wehave found that activatedmicro-
glia in ALS mice show a neurodegeneration-specific phenotype
that differs from LPS-activated microglia and M1 or M2 macro-
phages. It is likely that the genomic profiles of microglia in each
neurological disease context will be unique. Therefore, similar
analyses in mouse models of Parkinson’s disease, AD, and
Huntington’s disease may reveal different roles of microglia in
each neurological disease context. The data presented here
should provide a valuable resource for interpreting these studies.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6, B6.SOD1G93A, B6/SJL.SOD1G93A transgenic, and SOD1WT trans-
genic mice (Jackson Laboratories) were bred and maintained in full-barrier
facilities. Onset of motor weakness, including hindlimb tremors and weight
loss, and disease end stage were measured as previously described (Chiu
et al., 2008). For LPS activation, C57BL/6 mice were injected once intraperito-
neally with 5 mg/kg Escherichia coli LPS O55:B55 (Sigma Aldrich), and spinal
cord microglia were isolated 48 hr later. All studies were conducted according
to institutional guidelines for animal use and care at Harvard Medical School,
Harvard University, and Columbia University Medical Center.
Microglia Purification and Spinal Cord Flow Cytometry
Spinal cord immune cells were analyzed by FACS as previously described
(Chiu et al., 2008, 2009). FACS data are given in Table S4. Microglia were pu-
rified by sequential Percoll gradient centrifugation andmagnetic bead isolation
(Figures 1A and S1B), in a procedure modified from previous protocols (Car-
dona et al., 2006a; Hickman et al., 2008). Details regarding the FACS and
cell purification protocols are provided in Extended Experimental Procedures.
Deep Sequencing and Expression Analysis
RNA was extracted from purified microglia and subjected to paired-end RNA-
seq on the Illumina platform. Read alignment and gene levels were calculated
with the use of Bowtie, Cufflinks, and Tophat software. We conducted expres-
sion comparisons and clustering using GenePattern analysis modules (Broad
Institute), pathway analysis using DAVID and iPAGE (Goodarzi et al., 2009),
motif analysis using FIRE (Elemento et al., 2007), and T cell microglia transcrip-
tome analysis using iPAGE. Details regarding the RNA processing, data
analysis, immunostaining, and qPCR validation of expression analysis are pro-
vided in Extended Experimental Procedures.
ACCESSION NUMBERS
The NCBI GEO accession number for the raw FastQ sequencing data and
processed normalized expression data (RPKM) reported in this paper is
GSE43366.this pathway diagram (adapted from KEGG).
by the fold difference between SOD1G93A and control microglia. Genes whose
enase, cytochrome C oxidase, and other AD pathway genes are differentially
y RNA-seq and qPCR analysis (*p < 0.05; **p < 0.01; ***p < 0.001 by t test). Error
throughout the ventral horns of SOD1G93A compared with non-Tg spinal cords.
ale bars: 50 mm.
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